Randomised crossover trial to assess the tolerability of LHRH analogue administration

Prostate Cancer and Prostatic Diseases

Volumn 6, Issue 2, 2003, Pages 187-189

  Williams, G ^a   Lindsay, S ^a   Bowsher, W G ^a  

^a ROYAL GWENT HOSPITAL   (United Kingdom)

Author keywords

LHRH analogues; Patient discomfort; Tolerability

Indexed keywords

GONADORELIN DERIVATIVE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG PELLET; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LIQUID; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; VISUAL ANALOG SCALE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; GOSERELIN; HUMANS; INJECTIONS, SUBCUTANEOUS; LEUPROLIDE; MALE; MIDDLE AGED; PAIN; PROSTATIC NEOPLASMS;

EID: 0038082077     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500625     Document Type: Article

References (2)

1. Pienta KJ. Etiology epidemiology, and prevention of carcinoma of the prostate. In: Walsh PC, Retik AB, Darracott Vaughan E, Wein AJ, (eds). Campbells Urology, (7th edn.) WB Saunders Company, Philadelphia, pp 2489-2496. (1998)
2. The RCR COIN/BAUS Prostate Cancer Working Group. Guidelines on the management of prostate cancer. BJU Int 84: 987-1014. (1999)